The Department of Defense (DoD) is offering its Duchenne Muscular Dystrophy Investigator-Initiated Research Award (IIRA) to accelerate promising translational research into clinical applications for DMD. This grant supports mid-stage or later translational projects, including early-phase, proof-of-principle clinical trials, correlative studies, and preclinical studies utilizing animal models or human samples. Applications must include preliminary data relevant to Duchenne Muscular Dystrophy and adhere to rigorous study design standards, encompassing randomization, blinding, and appropriate data handling. This award explicitly excludes target discovery, drug screening, mechanism of action, or hypothesis-driven pathophysiology studies. Collaborative research, particularly between laboratory and clinical scientists, or across academic and industry sectors, is strongly encouraged.
Opportunity ID: 236015
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-13-DMDRP-IIRA |
| Funding Opportunity Title: | DoD Duchenne Muscular Dystrophy Investigator-Initiated Research Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | CategoryExplanation |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 2 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jun 06, 2013 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Nov 06, 2013 |
| Current Closing Date for Applications: | Nov 06, 2013 |
| Archive Date: | Dec 06, 2013 |
| Estimated Total Program Funding: | $2,020,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The DMDRP Investigator-Initiated Research Award (IIRA) mechanism was first offered in FY11. Since then, 40 IIRA applications have been received, and 7 have been recommended for funding. The DMDRP IIRA supports translational research that will accelerate the movement of promising ideas in DMD into clinical applications. Translational research may be defined as an integration of basic science and clinical observations with the specific goal of developing new therapies. While the ultimate goal of translational research is to move an observation forward into clinical application, translational research is most effective as a two-way continuum between the bench and the bedside. Within this continuum, the IIRA supports mid-stage or later translational research projects, including early-phase, proof-of-principle clinical trials and DoD FY13 DMDRP Investigator-Initiated Research Award 4 correlative studies to better inform the development of drugs, devices, and other DMD interventions. Research projects may also include preclinical studies in animal models, human subjects, and human anatomical substances. All projects should adhere to a core set of reporting standards for rigorous study design. The standards are described fully in www.nature.com/nature/journal/v490/n7419/full/nature11556.html. While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies and should be applied to those projects as well. Studies proposed under this award mechanism should not include: Target discovery Drug screening Mechanism of action studies Hypothesis-driven pathophysiology studies Applications must include preliminary data that are relevant to DMD and the proposed project. Clinical trials are supported by this award mechanism. Optional Qualified Collaborator: The FY13 DMDRP strongly supports collaborative research between laboratory scientists and clinical researchers, and between academic scientists and biotechnology/pharmaceutical industry scientists. Collaborations that bring new perspectives from other disciplines, or bring new investigators into the DMD field, are also strongly encouraged. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 help@cdmrp.org Email:help@cdmrp.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 236015 Full Announcement-1 -> dmdrp_fy13 iira pa _gg.pdf
Folder 236015 Full Announcement-1 -> dmdrp_fy13 iira trainee eligibility statement_final.pdf
Packages
| Agency Contact Information: | CDMRP Help Desk Phone: 301-682-5507 help@cdmrp.org Email: help@cdmrp.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00179097 | Jun 06, 2013 | Nov 06, 2013 | View |
Package 1
Mandatory forms
236015 RR_SF424_1_2-1.2.pdf
236015 PerformanceSite_1_4-1.4.pdf
236015 RR_Budget-1.1.pdf
236015 RR_KeyPersonExpanded_1_2-1.2.pdf
Optional forms
236015 RR_SubawardBudget30-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
